en
jalali
1396
6
1
gregorian
2017
9
1
11
3
online
1
fulltext
en
The Effect of SB431542 TGF-β Receptor Inhibitor, on HCV Replication in PBMCs of Patients with Chronic Hepatitis
Background and Aims: TGF-β is an effective cytokine in the viral replication cycle, which is also highly relevant to the pathogenesis of some viral infections. TGF-β induction by viral proteins is one of the ways to escape the virus from the immune system by inhibiting interferon signaling and other immune system factors. In recent years, the role of TGF-β and its inhibitory signaling has been confirmed in clinical trials. In this study, using SB431542, a TGF-β type I activin receptor like kinase inhibitor, the effect of TGF-β reduction on IFN expression and antiviral activity in PBMCs of patients with chronic hepatitis C was investigated.
Materials and Methods: PBMCs from 10 patients with chronic hepatitis and 5 healthy individuals were isolated with Ficoll solution and cultured in the presence of different concentrations of sb431542. RNA was extracted at different time points of culture, with Qiazol lysis reagent and cDNA was synthesized with commercial kits. The relative expression levels of TGF-β, IFN-α and HCV Core mRNA were determined using with REAL TIME PCR. The expression level of TGF-β protein was also measured in supernatant of cultured cells by ELISA method.
Results: The inhibitory effect of different concentrations of SB431542 at various time point showed that it peaks 48h after treatment and the maximum increase of IFN-α expression and significant antiviral effects reached 72 h after treatment.
Conclusions: The effects of TGF-β on IFNs may be correlated with inverse ratio depending on the level and duration of expression, which indicates the regulatory role of these proteins in the immune system against the viruses. TGF inhibitory drugs can augment immune system against the viruses.
TGF-β, IFN-α, SB431542
1
6
http://journal.isv.org.ir/browse.php?a_code=A-10-137-1&slc_lang=en&sid=1
2018/03/7
1396/12/16
2018/09/7
1397/6/16
Hamzeh
Choobin
Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
H.chubin13@gmail.com
0031947532846006706
0031947532846006706
No
Taravat
Bamdad
Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Bamdad_T@modares.ac.ir
0031947532846006707
0031947532846006707
Yes
Mehdi
Shekarabi
Associate professor Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran
m_shekarabi@yahoo.com
0031947532846006708
0031947532846006708
No
en
Heamagglutinin Conserved Domain (HA2) Prepared in Prokaryotic System is Immunogenic in Mice but not Protective against Lethal Influenza Challenge
Background and Aims: Influenza vaccine production process is time-consuming with little-to-no cross-protection which requires annual adjustment. The construction of a universal vaccine to deal with the pandemics and epidemics which occasionally threat human population is the aim of many researches worldwide. Today, influenza vaccines are mostly against two major antigenic proteins, hemagglutinin and neuraminidase. As compared to high variable globular head, the hemagglutinin stalk domain is more conserved among different subtypes of influenza A viruses which could be a good candidate to develop a cross-protective vaccine.
Materials and Methods: In this study, recombinant HA2 protein comprising fusion peptide was expressed in E.coli, purified using Ni-TED columns, refolded and desalted by dialysis. BALB/c mice in different groups were immunized with HA2 alone or supplemented with Alum or Alum/CPG. Vaccinated mice sera were examined for anti-HA2 specific IgG responses. Finally, mice were challenged with one LD90 of mouse-adapted A/PR8 virus.
Results: The results showed that HA2 recombinant protein could provoke immunogenicity in BALA/c mice and this immune response could be elevated with Alum and Alum/CpG. Despite promising immune responses, there was insignificant protection of HA2-immunized mice when challenged with the mouse-adapted strain A/PR8.
Conclusions: Therefore, HA2 protein alongside with other influenza virus conserved proteins should be studied to achieve a suitable vaccine formulation for broad spectrum cross-reactive immune responses.
influenza virus, Hemagglutinin, CPG, Alum
7
12
http://journal.isv.org.ir/browse.php?a_code=A-10-59-1&slc_lang=en&sid=1
2018/03/72018/06/13
1397/3/23
2018/09/72018/09/7
1397/6/16
Saeideh
Sadeghi Neshat
Department of Influenza and other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran
bio_sa_n@yahoo.com
0031947532846006709
0031947532846006709
No
Behrokh
Farahmand
Department of Influenza and other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran
farahmand.b2@gmail.com
0031947532846006710
0031947532846006710
No
Somayeh
Zamani
Department of Influenza and other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran
zamani.s@yahoo.com
0031947532846006711
0031947532846006711
No
Vahideh
Mazaheri
Department of Influenza and other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran
mazaherivahideh@gmail.com
0031947532846006712
0031947532846006712
No
Ali
Torabi
Department of Influenza and other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran
aliitorabi@yahoo.com
0031947532846006713
0031947532846006713
No
Fatemeh
Fotouhi
Department of Influenza and other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran
fotouhi@pasteur.ac.ir
0031947532846006714
0031947532846006714
Yes
en
Investigation of the Relationship between HTLV-1 Infection and MMP-3 Gene Expression in HTLV-1 Positive Cardiac Patients
Background and Aims: Human T-lymphotropic virus type 1 (HTLV-1) is a member of retroviridae family that causes ATL and HAM/TSP. Many inflammatory diseases are associated with this virus, such as Sjögren's syndrome, Hashimoto's thyroiditis, Uveitis and also Atherosclerosis. HTLV-1 performs in long latency period and can activate the immune responses in coronary vessels. Activated immune system produces inflammatory factors such as TNF-α cytokine that can increase Matrix Metalloproteinases as a main factor in patients with coronary artery diseases (CAD). We aimed to determine the relation between this virus infection and MMP-3 expression in Atherosclerosis patients.
Materials and Methods: 44 patients (13 individuals CAD+ HTLV-1+, 8 individuals CAD- HTLV-1+, 13 individuals CAD+ HTLV-1- and 10 individuals CAD- HTLV-1-) were selected and MMP-3 gene expression was measured by Real-time polymerase chain reaction. Results: There was no significant correlation between MMP-3 gene expression and HTLV-1 expression level in HTLV-1-positive cardiac and Atherosclerosis patients.
Conclusions: Although the main risk factor in Atherosclerosis patients is MMP-3, despite our expectation, no significant correlation was observed in our statistical analysis within four examined groups (p≥0.05). This evaluation showed higher MMP-3gene expression but not significant in CAD+ HTLV-1+ group compared to CAD+ HTLV-1- group. The larger sample sizes may help to improve the outcome to reach a significant level.
HTLV-1, MMP-3, TNF-α, Atherosclerosis, Real-time PCR
13
18
http://journal.isv.org.ir/browse.php?a_code=A-10-140-1&slc_lang=en&sid=1
2018/03/72018/06/132018/06/14
1397/3/24
2018/09/72018/09/72018/09/7
1397/6/16
Mina
Mohammadhosayni
Department of Immunology, Faculty of Medicine, Shahed University, Tehran, Iran
mobinhuseyni@yahoo.com
0031947532846006715
0031947532846006715
No
Fatemeh
Hajighasemi
Department of Immunology, Faculty of Medicine, Shahed University, Tehran, Iran
hajghasemi@gmail.com
0031947532846006716
0031947532846006716
No
Abdolrahim
Rezaee
Inflammation and Inflammatory Diseases Division, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
RezaeeR@mums.ac.ir
0031947532846006717
0031947532846006717
No
Farnaz
Mozayani
Inflammation and Inflammatory Diseases Division, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
MozayaniF881@gmail.com
0031947532846006718
0031947532846006718
No
Fatemeh Sadat
Mohammadi
Inflammation and Inflammatory Diseases Division, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Fs_mohamadi55@yahoo.com
0031947532846006719
0031947532846006719
No
Nastaran
Tarban
Department of Biology, Kish International Campus, University of Tehran, Kish, Iran
nastarantarban88@gmail.com
0031947532846006720
0031947532846006720
No
Navid
Momenifar
Faculty of Basic Sciences and Advanced Technologies in Biology, Department of Cell and Molecular Biology Science, University of Science and Culture, ACECR, Tehran, Iran
na.momenifar@gmail.com
0031947532846006721
0031947532846006721
No
Mehdi
Norouzi
Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
mnorouzi@tums.ac.ir
0031947532846006722
0031947532846006722
Yes
en
Comparison of PEG Interferon Loaded and non-Loaded Iron Oxide Nanoparticles on Hepatitis C Virus Replication in Cell Culture System
Background and Aims: Iron oxide nanoparticles are among the most effective tools which can replace current medical techniques for diagnosis and treatment of various diseases. Hepatitis C infection is one of the main health problems in the world, affecting around 3% of the world's population. This infection can develop into liver cirrhosis and liver cancer over the time in 80% of patients.
In this study, the effects of PEG interferon loaded iron oxide nanoparticles on hepatitis C virus infection compared with unloaded nanoparticles was studied in vitro.
Materials and Methods: First, Huh7.5 cells were cultured to replicate the hepatitis C virus. After loading the peg interferon alpha on iron oxide nanoparticles, their effects on the replication of hepatitis C virus was investigated by several methods.
Results: The results of this study showed that iron oxide nanoparticles and peg interferon loaded iron oxide nanoparticles were able to reduce the load of hepatitis C virus in infected cell culture, but differences were not statistically significant.
Conclusions: These data indicated that hepatitis C viral load was decreased in infected cells after induction of PEG interferon loaded iron oxide nanoparticles, but it needs more research to clarify in animal models or even to examine with other types of bare and drug-loaded nanoparticles in a similar way to our study.
Hepatitis C Virus, Nanoparticles, Iron Oxide, Hepatitis C Virus Treatment, Peg Interferon
19
26
http://journal.isv.org.ir/browse.php?a_code=A-10-120-6&slc_lang=en&sid=1
2018/03/72018/06/132018/06/142018/12/10
1397/9/19
2018/09/72018/09/72018/09/72018/12/10
1397/9/19
K
Ketabi
Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
0031947532846006723
0031947532846006723
No
E
Aryan
Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
0031947532846006724
0031947532846006724
No
M
Darroudi
Nuclear Medicine Research Center (NMRC), Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
0031947532846006725
0031947532846006725
No
H
Farsiani
Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
0031947532846006726
0031947532846006726
No
A
Hooshyar Chichaklu
Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
0031947532846006727
0031947532846006727
No
M
Damavandi
Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
0031947532846006728
0031947532846006728
No
A
Gholoobi
Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
0031947532846006729
0031947532846006729
No
S
Naseri
Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
0031947532846006730
0031947532846006730
No
M
Abdoli
Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
0031947532846006731
0031947532846006731
No
Z
Meshkat
Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
0031947532846006732
0031947532846006732
Yes
en
Detection of CMV and EBV DNA in PBMCs of MS Patients and Healthy Individuals in Gorgan, Iran
Background and Aims: Multiple Sclerosis is a chronic and autoimmune disease, which causes inflammation and demyelination of the axons in CNS. Studies have indicated that Herpesviruses might be one of the potential environmental elements that can trigger the initiation of the inflammatory cascade in MS. The purpose of this study was to determine whether the genome of CMV and (or) EBV is present in PBMCs of the MS patients and healthy individuals and if so, consider the sequencing process for DNA-positive samples.
Materials and Methods: Blood samples from 50 MS patients and healthy people were collected and extraction of DNA was done on PBMCs of the mentioned samples. PCR was used for conserved and variable regions of the genome to seek the presence of EBV and (or) CMV DNA in extraction products.
Results: Neither in PBMCs samples of the MS patients (n=50) nor in those of healthy individuals (n=50) could we find any evidence to prove the presence of the two mentioned viral DNAs in DNA extraction products of the PBMCs samples. Genotyping of mentioned viruses was consequently omitted from the study purposes.
Conclusions: Based on the findings in this study, there seems to be no significant relation between CMV/EBV infection and the risk of MS development.
CMV, EBV, Multiple Sclerosis, PCR
27
32
http://journal.isv.org.ir/browse.php?a_code=A-10-153-1&slc_lang=en&sid=1
2018/03/72018/06/132018/06/142018/12/102018/08/5
1397/5/14
2018/09/72018/09/72018/09/72018/12/102018/12/10
1397/9/19
Seyed Abbas
Tazarghi
Department of Microbiology, Golestan University of Medical Sciences, Gorgan, Iran
Tazarghi@yahoo.com
0031947532846006733
0031947532846006733
No
Alijan
Tabarraei
Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran
alijant@yahoo.com
0031947532846006734
0031947532846006734
Yes
MH
Naeimi
0031947532846006735
0031947532846006735
No
A
Moradi
0031947532846006736
0031947532846006736
No
A
Ahmadi
0031947532846006737
0031947532846006737
No
N
Javid
Department of Microbiology, Golestan University of Medical Sciences, Gorgan, Iran
0031947532846006738
0031947532846006738
No
en
Challenges and Perspectives towards the Development of more Effective Influenza Vaccine
Influenza viruses continue to be a major health threat in human and bird populations. The improvements in formulation and production level of the current influenza vaccines are not sufficient to afford complete protection. The continuous antigenic drifts and emergence of endemic and zoonotic strains make influenza vaccine planning difficult. Concern about the emergence of new influenza pandemic provides subject for developing a universal influenza vaccine to be most effective in preventing influenza A either by targeting the HA or other viral proteins. The recombinant and synthetic antigens used in influenza vaccine research and development are generally less immunogenic and need to incorporate novel adjuvants with modified delivery carriers to develop broad-protective vaccines.
Influenza virus, vaccine, adjuvant, delivery system
33
40
http://journal.isv.org.ir/browse.php?a_code=A-10-134-2&slc_lang=en&sid=1
2018/03/72018/06/132018/06/142018/12/102018/08/52018/02/3
1396/11/14
2018/09/72018/09/72018/09/72018/12/102018/12/102018/08/19
1397/5/28
Maryam
Ahmadi
Razi Vaccine & Serum Research Institute
m.ahmadi@rvsri.ac.ir
0031947532846006739
0031947532846006739
No
Shahla
Shahsavandi
Razi Vaccine & Serum Research Institute
s.shahsavandi@rvsri.ac.ir
0031947532846006740
0031947532846006740
Yes